2025-09-14 - Analysis Report
Okay, here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the information you provided.  The report is in English, starts with key numbers, and then adds more detailed analysis.

**TMDX Stock Analysis**

**0. Executive Summary**

TransMedics Group Inc. (TMDX) is a medical technology company revolutionizing organ transplant therapy.  TMDX has significantly outperformed the S&P 500 (VOO) over the analyzed period, with high growth potential and strong recent earnings, but also exhibits high volatility and risk. Recent news and analyst ratings are largely positive, but a recent price dip and a medium risk market indicator suggest caution.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** TMDX
*   **Company:** TransMedics Group Inc
*   **TMDX Cumulative Return:** 213.24%
*   **VOO Cumulative Return:** 78.09%
*   **Absolute Difference:** 135.15%
*   **Deviation (Spread) Metrics:**
    *   Max Deviation: 594.7
    *   Min Deviation: -88.7
    *   Current Deviation: 260.7
    *   Relative Deviation: 51.1 (Indicates the current deviation is in the middle of its historical range relative to the S&P 500).

**Alpha/Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha   | Beta   | Cap(B) |
| ---------- | -------- | -------- | ------- | ------ | ------ |
| 2019-2021  | -4.0%    | 63.4%    | -52.0%  | 0.1    | 0.7    |
| 2020-2022  | 140.0%   | 68.3%    | 133.0%  | 0.2    | 2.1    |
| 2021-2023  | 95.0%    | 69.4%    | 75.0%   | 0.4    | 2.7    |
| 2022-2024  | 147.0%   | 82.8%    | 120.0%  | 0.4    | 2.1    |
| 2023-2025  | 94.0%    | 82.8%    | 40.0%   | 0.6    | 3.9    |

**Analysis:**

*   TMDX has significantly outperformed the S&P 500, indicating substantial alpha generation.
*   The Beta values are relatively high, indicating TMDX is more volatile than the S&P 500.  This is confirmed by MDD numbers.
*   The CAGR is very high.
*   The Alpha is also consistently high, showcasing TMDX's ability to generate returns independent of the market.
*   The significant drawdowns (MDD) highlight the stock's volatility.

**2. Recent Price Action**

*   **Current Price:** $114.56
*   **Last Market Data:**
    *   Price: $114.56
    *   Previous Close: $116.99
    *   Change: -$2.07
*   **Moving Averages:**
    *   5-Day Moving Average: $110.64
    *   20-Day Moving Average: $114.64
    *   60-Day Moving Average: $118.47

**Analysis:**

*   The stock price is currently below the 20-day and 60-day moving averages, suggesting a short-term downtrend.
*   The recent price drop (change of -$2.07) indicates selling pressure.
*   The 5-day moving average is below the 20-day, further supporting the downtrend.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 42.87 (Neutral - Not Overbought or Oversold)
*   **PPO:** 0.15 (Close to signal line)
*   **Hybrid Signal:** Cash_6%_Buy 90% of cash (1157 shares - Safe - MRI:0.32)
*   **20-Day Relative Deviation Change:** -0.9 (Negative - Short-term Decline)
*   **Expected Return:** 174.3% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests a low-risk environment.  However, it's important to remember that this is a relative measure and doesn't eliminate risk entirely.
*   The RSI indicates neutral momentum.
*   The negative change in relative deviation suggests underperformance relative to the S&P 500 over the last 20 days.
*   The Hybrid Signal suggests a buy recommendation, allocating 90% of available cash.
*   The high expected return indicates substantial long-term growth potential.
*   The price drop is significant and reflects immediate market concerns, suggesting a possible pullback or correction.

**4. Recent News & Significant Events:**

*   **[2025-09-10]** Bullish Wall Street outlook (Insider Monkey)
*   **[2025-09-08]** Top Growth Stock for the Long-Term (Zacks)
*   **[2025-09-04]** Stifel Initiates at Neutral with $115 Price Target (MT Newswires)
*   **[2025-08-29]** Reasons to Retain TransMedics Stock (Zacks)
*   **[2025-08-29]** Down 1.9% Since Last Earnings (Zacks)
*   **[2025-08-28]** Upward 2025 Earnings Revisions (Simply Wall St.)

**Analysis:**

*   Recent news is mixed. There's generally positive sentiment regarding long-term growth and potential, as reflected in the bullish articles and upward earnings revisions.  However, Stifel's "Neutral" rating and the report about the stock being down since the last earnings release indicate some caution.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (~1.78)
*   **Number of Opinions:** 8
*   **Target Price:**
    *   Average: $138.88
    *   High: $170.00
    *   Low: $114.00
*   **Recent Rating Changes:** (No changes provided - needs more info)

**Analysis:**

*   The analyst consensus is "Buy," indicating positive expectations for the stock.
*   The average target price ($138.88) suggests potential upside from the current price ($114.56).
*   The range of target prices is quite wide, suggesting varying degrees of optimism among analysts.
*   Need information regarding recent rating changes to provide more insightful analysis.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 예상 EPS |
| ---------- | ---- | -------- |
| 2025-07-30 | 0.92 | 0.48     |
| 2025-05-08 | 0.7  | 0.29     |
| 2025-02-27 | 0.19 | 0.22     |
| 2024-10-28 | 0.12 | 0.29     |
| 2024-07-31 | 0.35 | 0.21     |

**Analysis:**

*   TMDX has consistently beaten EPS estimates in recent quarters, demonstrating strong earnings performance and efficient financial management.
*   The substantial difference between actual and expected EPS in 2025-07-30 and 2025-05-08 indicates a potential underestimation of the company's growth trajectory.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| ------------ | ---------- | ------------- |
| 2025-06-30   | $0.16B     | 61.38%        |
| 2025-03-31   | $0.14B     | 61.47%        |
| 2024-12-31   | $0.12B     | 59.21%        |
| 2024-09-30   | $0.11B     | 55.94%        |
| 2024-06-30   | $0.11B     | 60.59%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
| ------------ | ---------- | --------- |
| 2025-06-30   | $0.32B     | 10.97%    |
| 2025-03-31   | $0.27B     | 9.64%     |
| 2024-12-31   | $0.23B     | 3.00%     |
| 2024-09-30   | $0.21B     | 2.01%     |
| 2024-06-30   | $0.19B     | 6.42%     |

**Analysis:**

*   **Revenue:**  Revenue has been consistently increasing over the past year, indicating strong growth in the company's sales and market penetration.
*   **Profit Margin:** Profit margins are very high and stable, suggesting strong pricing power and efficient cost management.
*   **Equity:** Equity has been growing, indicating financial stability and successful capital management.
*   **ROE:**  ROE has seen significant improvement, showing increased profitability relative to shareholder equity.

**7. Overall Summary & Recommendation**

TMDX presents a compelling, albeit risky, investment opportunity.  The company exhibits strong growth, high profitability, and significant outperformance compared to the S&P 500.  Analyst ratings are generally positive, and recent earnings have been impressive.

**Key Considerations:**

*   **High Volatility:** The high Beta and MDD indicate that TMDX is more volatile than the market, requiring a higher risk tolerance.
*   **Recent Price Dip:** The recent price drop and negative change in relative deviation suggest potential short-term weakness.
*   **Mixed News:** While most news is positive, some reports indicate potential challenges.
*   **Long-Term Growth Potential:** The high expected return and analyst consensus suggest significant long-term growth prospects.
*   **Premium Valuation:** This stock has a premium valuation; continued revenue and profit growth is required to justify the high multiples.

**Recommendation:**

*   **Long-Term Investors:** For investors with a long-term horizon (2+ years) and a high-risk tolerance, TMDX could be a worthwhile addition to a diversified portfolio. Consider dollar-cost averaging to mitigate the impact of volatility.
*   **Short-Term Investors:** Short-term investors should exercise caution due to the recent price dip and high volatility. Consider waiting for a potential consolidation or reversal before entering a position.
*   **Risk Management:** Always implement appropriate risk management strategies, such as stop-loss orders, to protect your capital.
